急性拉莫三嗪过量的临床效应(ATOM-10)
这项前瞻性观察研究纳入54例急性拉莫三嗪过量(≥2 g)患者,中位摄入量4.8 g,76%合并摄入其他物质。镇静81%、气管插管54%、心动过速72%、低血压39%(28%用正性肌力药)、癫痫20%、5-羟色胺毒性43%。较高的拉莫三嗪峰浓度与气管插管(P<0.0001)、低血压用正性肌力药(P=0.0269)、癫痫(P=0.0002)相关。合并摄入其他5-羟色胺能药物者5-羟色胺毒性发生率67% vs 5%(P<0.0001)。昏迷、癫痫和低血压似乎呈浓度依赖性;5-羟色胺毒性与拉莫三嗪浓度无关。
要点
- 急性拉莫三嗪过量(≥2 g)患者中,镇静81%、气管插管54%、癫痫20%、低血压39%(28%用正性肌力药)。
- 较高的峰浓度与气管插管(P<0.0001)、低血压用正性肌力药(P=0.0269)、癫痫(P=0.0002)相关。
- 合并摄入其他5-羟色胺能药物者5-羟色胺毒性发生率为67%(22/33),未合并者为5%(1/21),P<0.0001。
- 5-羟色胺毒性43%(23例),其中4例为严重毒性(体温>38.5 °C和/或强直,接受肌肉松弛治疗)。
- 作者认为,拉莫三嗪过量后的昏迷、癫痫和低血压似乎呈浓度依赖性。
适用人群与场景
- 年龄>14岁、急性拉莫三嗪过量(摄入≥2 g)的患者,来自澳大利亚毒物监测研究或三个毒理学单位。
诊断标准与关键阈值
- 急性拉莫三嗪过量定义为摄入≥2 g。
- 5-羟色胺毒性严重者定义为体温>38.5 °C和/或强直并接受肌肉松弛治疗。
处置流程与药物剂量
- 镇静44例(81%),其中29例(54%)行气管插管。
- 低血压21例(39%),其中15例(28%)使用正性肌力药。
- 5-羟色胺毒性严重者(体温>38.5 °C和/或强直)接受肌肉松弛治疗。
红旗征与不能漏的情况
- 昏迷需气管插管:与较高峰浓度相关(P<0.0001)。
- 低血压需正性肌力药:与较高峰浓度相关(P=0.0269)。
- 癫痫发作:与较高峰浓度相关(P=0.0002)。
- 严重5-羟色胺毒性:体温>38.5 °C和/或强直,需肌肉松弛治疗。
研究设计与关键结果
- 前瞻性观察研究,2020年7月至2024年3月,纳入54例急性拉莫三嗪过量(≥2 g)患者,中位年龄29岁(IQR 21-42岁),女性37例(69%)。
- 中位摄入剂量4.8 g(IQR 3.2-6.3 g),41例(76%)合并摄入其他物质。
- 中位最大拉莫三嗪浓度为18.5 mg/L(IQR 12.4-25.0 mg/L),达峰时间中位4.3 h(IQR 3.2-10.8 h)。
- 临床效应:镇静44例(81%),气管插管29例(54%),心动过速39例(72%),低血压21例(39%),使用正性肌力药15例(28%),癫痫11例(20%)。
- 5-羟色胺毒性23例(43%),其中4例为严重毒性(体温>38.5 °C和/或强直,接受肌肉松弛治疗)。
- 较高的峰浓度与气管插管(P<0.0001)、低血压使用正性肌力药(P=0.0269)、癫痫(P=0.0002)相关。
- 合并摄入其他5-羟色胺能药物(部分为治疗剂量)者5-羟色胺毒性发生率为67%(22/33),未合并者为5%(1/21),P<0.0001。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,拉莫三嗪过量后的昏迷、癫痫和低血压似乎呈浓度依赖性,临床中需对摄入≥2 g的患者警惕昏迷、癫痫和低血压,并按需行气管插管、使用正性肌力药。
- 作者认为,5-羟色胺毒性发生于合并摄入其他5-羟色胺能药物者,且与拉莫三嗪浓度无关;对合并摄入其他5-羟色胺能药物者需警惕5-羟色胺毒性(发生率为67% vs 5%,P<0.0001)。
指南或共识出处
- Clin Toxicol (Phila) 发表的 ATOM-10 研究。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Lamotrigine overdose is not typically associated with severe toxicity. However, both severe toxicity and serotonin toxicity is occasionally reported following large ingestions. We aimed to investigate the clinical effects of lamotrigine overdose.
METHODS: This was a prospective observational study from July 2020-March 2024. Patients >14 years-old with acute lamotrigine overdose (≥2 g ingestion) were recruited from the Australian Toxicology Monitoring study or identified from three toxicology units. Data extracted included clinical features, lamotrigine concentrations, management, and outcomes.
RESULTS: Fifty-four patients were included, median age 29 years (IQR: 21-42 years), 37 (69%) were female. The median ingested dose was 4.8 g (IQR: 3.2-6.3 g) and 41 patients (76%) co-ingested other substances. The median maximum lamotrigine concentration was 18.5 mg/L (IQR: 12.4-25.0 mg/L) at a median time of 4.3 h (IQR: 3.2-10.8 h) post-ingestion. Clinical effects and their management included sedation in 44 (81%) with 29 patients (54%) endotracheally intubated, tachycardia in 39 (72%), hypotension in 21 (39%) with 15 (28%) receiving inotropes, and seizures in 11 (20%). Serotonin toxicity occurred in 23 (43%) patients with four having severe toxicity characterised by temperature >38.5 °C and/or rigidity treated with muscle paralysis. Higher peak lamotrigine concentrations were correlated with severe outcomes such as endotracheal intubation for coma (P <0.0001), patients with hypotension receiving inotropes (P = 0.0269) and patients developing seizures (P = 0.0002). Patients who co-ingested another serotonin agent (some in therapeutic doses) had a higher incidence of developing serotonin toxicity (22/33 [67%]) versus those who had not (1/21 [5%]); P <0.0001).
DISCUSSION: Severe toxicity was associated with higher peak lamotrigine concentrations. Serotonin toxicity was common in those who were exposed to another serotonergic agent.
CONCLUSION: Coma, seizures and hypotension following lamotrigine overdose appeared to be concentration dependent. Serotonin toxicity occurred in those who co-ingested another serotonergic agent and was unrelated to lamotrigine concentration.
参考来源
- Chiew AL, Isbister GK, Nguyen K, et al. Clinical effects of acute lamotrigine overdose (ATOM-10). Clin Toxicol (Phila). 2025. PMID: 40126403. doi:10.1080/15563650.2025.2471906
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。